ANNIVERSARY REVIEW

50 years since the discovery of bromocriptine

G Michael Besser1, Ronald F Pfeiffer2 and Michael O Thorner3

1Medicine, St Bartholomew’s Hospital, London, UK, 2Neurology, Oregon Health & Science University, Portland, Oregon, USA, and 3Medicine, University of Virginia, Charlottesville, Virginia, USA

Abstract

Ergotism is the long-term ergot poisoning by ingestion of rye or other grains infected with the fungus Claviceps purpurea and more recently by excessive intake of ergot drugs. It has either neuropsychiatric or vascular manifestations. In the Middle Ages, the gangrenous poisoning was known as St. Anthony’s fire, after the order of the Monks of St. Anthony who were particularly skilled at treating the condition. In 1917, Prof. Arthur Stoll returned home to Switzerland from Germany, to lead the development of a new pharmaceutical department at Sandoz Chemical Company. Stoll, using the special methods of extraction learned from his work with his mentor Willstetter, started his industrial research work with ergot. He succeeded in isolating, from the ergot of rye, ergotamine as an active principle of an old popular remedy for excessive post-partum bleeding. The success of this discovery occurred in 1918 and was translated into a pharmaceutical product in 1921 under the trade name Gynergen. In subsequent work, Stoll and his team were leaders in identifying the structure of the many other alkaloids and amines produced by Claviceps purpurea. This was the cultural background and scientific foundation on which bromocriptine was discovered.

Introduction

It is 50 years since the discovery of 2-Br-α-bromoergokryptine mesylate, (CB154) bromocriptine (1). Today, no one questions the importance of dopamine agonist drugs in therapy of endocrine and neurological diseases. Not so in the early 1970s. It was at this exciting time in neuroendocrinology that the hypothalamic hormones were being identified, isolated and sequenced and then studied in man. It is worth recounting the story of bromocriptine’s discovery as it is quite remarkable and reflects the wisdom and perseverance of its founder, Prof. Edward Flückiger.

Invited Author’s profile

Michael O Thorner, Emeritus Professor of Medicine, University of Virginia, has studied hypothalamic pituitary physiology and pathophysiology. His contributions include the demonstration that prolactin-secreting pituitary tumors can be treated with dopamine agonist drugs, and identification of pancreatic tumor in a patient with acromegaly. His research interest has been the decline of growth hormone secretion during aging and its reversibility with growth hormone secretagogues. He has been made Fellow, American Academy of Arts and Sciences, Master, American College of Physicians (ACP), and received ACP John Phillips Memorial Award, Endocrine Society Edwin B. Astwood, Distinguished Physician and Fred Conrad Koch Awards, and the Dale Medal of the Society for Endocrinology.
Prof. Flückiger was working at Sandoz Pharmaceuticals, which is now Novartis. He set out to build on the work of Shelesnyak who was an American scientist working at the Weitzman Institute in Israel. In 1954, Shelesnyak published the first paper showing that the ergot extract known as ergotoxine, a mixture of ergocornine, ergocryptine and ergocristine, inhibited the formation of deciduomata in pseudopregnant rats and also interfered with early gestation in the rat by preventing progesterone production by the corpus luteum it prevented implantation of the fertilized ovum and thus had an anti-fertility effect (2, 3). He demonstrated that these effects were mediated by ergocornine and used it as an investigative pharmacological probe to help understand the mechanisms underlying the implantation of the fertilized ovum in the endometrium (4). He was studying rat physiology and through a series of logical and remarkable studies, he identified that ergocornine suppressed prolactin and that prolactin was responsible for sustaining the production of progesterone for the implantation of the fertilized ovum (4, 5).

Flückiger realized that ergocornine could not be used in humans due to its oxytocic and vascular effects (6). He therefore set out to modify its structure and bring out the prolactin-lowering action without the oxytocic or vascular effects. Bromocriptine was the compound which he made and which became the first dopamine agonist to be approved for treatment of patients.

The story is even more remarkable when considering that at that time C H Li, who had been responsible previously for isolating so many purified pituitary hormones, had stated that prolactin did not exist in the human and all lactogenic action in human blood could be explained by growth hormone (GH). Both GH and prolactin are equally effective in stimulating lactation, inhibition of implantation of the fertilized ovum or blocking pseudopregnancy. We now know that prolactin has different roles in humans than in the rat. It is not luteotrophic and suppression of prolactin restores fertility in patients with hyperprolactinemia. The next twist in the story was that bromocriptine was developed as an inhibitor of prolactin secretion in the human. Dopamine receptors had not yet been identified and it was unknown how ergocryptine or bromocriptine suppressed prolactin secretion.

Each one of these statements could be the subject of a whole article so here we would just like to point to some of the key observations and the investigators who made them. Andrew Frantz and Michael Besser and their respective colleagues at Columbia University, New York and St. Bartholomew’s Hospital in London finally demonstrated that prolactin and GH existed separately in the human. They developed new more sensitive bioassays. Instead of using the very insensitive pigeon crop assay, they used breast tissue in organ culture (from mice and rabbits respectively) and were able to show that prolactin-like lactogenic bioactivity existed in the circulation of patients with galactorrhea in whom GH levels were very low, and that further that this lactogenic activity could not be blocked by specific anti-GH antisera (7, 8, 9). The group at St. Bartholomew’s Hospital were the first investigators then allowed to perform clinical studies with bromocriptine; they did so in male and female patients with inappropriate lactation and hypogonadism who had been shown to have hyperprolactinemia. They demonstrated that bromocriptine (then known as CB154 or bromoergocriptine) rapidly lowered the elevated circulating prolactin levels and resulted in immediate reversal of the patients’ hypogonadism. Menstruation and potency returned even if the hypogonadism had been present for many years. The effect was dramatic (10). Similar studies confirming these effects were performed by Emilio del Pozo in Switzerland (11, 12).

As these clinical studies were underway, Robert MacLeod at the University of Virginia was studying the control of prolactin release from hemipituitaries in short-term culture. He was measuring prolactin at that time from a band on gel electrophoresis and showed that prolactin synthesis/secretion was suppressed by epinephrine, norepinephrine and dopamine (13). However, the anti-secretory effect was not blocked by alpha or beta blockade but was blocked by phenothiazines and haloperidol. Similarly, the inhibitory effect of ergocryptine could be blocked by these neuroleptic drugs, suggesting that there were new receptors involved. These were later shown to be D2 dopamine receptors. MacLeod was fighting an uphill battle in suggesting that the hypothalamic prolactin-inhibiting factor might be related to a catecholamine-like substance as the conventional wisdom at that time was that all hypothalamic regulatory hormones would be
peptides. Thus, to suggest that the prolactin-inhibiting hormone was dopamine was controversial (13).

Henry Friesen and his colleagues in Winnipeg in Canada ultimately isolated prolactin (14). Corrodi and Fuxe in Stockholm demonstrated that dopamine turnover was increased when prolactin was injected into the hypothalamus and that treatment of a rat with bromocriptine reduced dopamine turnover (15). All this supported MacLeod’s hypothesis. Later, dopamine was isolated from portal blood and it became generally accepted that dopamine is the prolactin-inhibiting hormone which tonically suppresses prolactin secretion (16).

The efficacy of bromocriptine in treating hyperprolactinemia was rapidly acknowledged. The diagnosis of hyperprolactinemia increased dramatically as physicians became aware of its existence and it became the most common hypothalamic/pituitary disorder. We know that pituitary tumors are common and approximately 50% of them are prolactinomas. In women with menstrual dysfunction who harbored small tumors and hyperprolactinemia reliably could be treated with bromocriptine with restoration of normal gonadal function (10, 12, 17). Their prior dysfunction included menstrual dysfunction ranging from amenorrhea to oligomenorrhea and luteal dysfunction. Measurement of a serum prolactin could easily diagnose hyperprolactinemia. Men with hyperprolactinemia have lack of libido and impotence which are reversed with bromocriptine therapy. Initially, it was unclear whether bromocriptine had an effect on the pituitary tumor size and therefore many patients had pituitary radiation therapy or transsphenoidal or transfrontal surgery. These therapies rarely normalized the prolactin. Michael Thorner was fortunate when he arrived at the University of Virginia to be referred a young man with a very large pituitary tumor, severe visual field defects, severe headaches and hypogonadism. The standard of care at that time in such patients with large pituitary tumors was neurosurgical – attempted removal. This patient refused and he was offered experimental medical treatment as an inpatient. Following receiving appropriate approval from the Human Investigation Committee, the patient was admitted and following the first dose of bromocriptine, his catastrophic headache improved and by day 3, his visual fields also began to improve (Fig. 1) and by 2 weeks, his pituitary tumor was shown to have reduced in size (18). Later, in collaboration with Kalman Kovacs in Toronto and George Tindall in Atlanta, pituitary tumors were collected from patients with pituitary macroadenomas who had been treated for 6 weeks prior to surgery. The prolactin tumor cells demonstrated that the volume of the tumor cells were reduced 20 fold, but this did not occur in the ‘non’-functioning tumors (19). Further, if treatment was stopped...
after a year of treatment, the tumor could re-expand and thus long-term therapy was required (20). The role of bromocriptine and the later developed dopamine agonists is established in patients with prolactinomas and is reviewed by Molitch (21). Today, cabergoline is the preferred drug due to its long duration of action such that it can be administered once or twice per week.

In his studies on GH secretion, Liuzzi and his colleagues in Italy had identified that L-Dopa stimulated GH secretion in normal subjects. However, there was a surprising and paradoxical suppression in patients with acromegaly (22). Several groups including those at St. Bartholomew’s Hospital in London and the Italian group performed studies in patients with acromegaly. It was not as effective as in prolactinomas, but it did lower GH and IGF-I levels in most but not all patients and most importantly relieved many of the symptoms including hyperhidrosis, joint pain and swelling of the digits so that ring size was reduced (23, 24, 25, 26). As the more active somatostatin analogs were introduced followed by the GH receptor antagonist pegvisomant, DA agonists became less used. However, it is an oral therapy and although higher doses are required than are needed in hyperprolactinemia, it can be effective particularly in patients with mild elevation of GH levels. As in prolactinomas, cabergoline is the drug of choice today for treatment by a dopamine agonist in acromegaly. This was reviewed by Giustina and colleagues (27).

Parkinson’s disease (28) and neurological indications: The introduction of levodopa in the 1960s had revolutionized the treatment of Parkinson’s disease (PD) (29). The initial response to levodopa often was dramatic and raised hopes that levodopa might even be a cure for the disorder. With the passage of time, however, it became clear that such was not the case. The response to levodopa frequently became marred by fluctuations in motor response, in which the duration of efficacy of a dose of levodopa became progressively shorter. Dyskinetic movements, typically choreiform in character, also appeared in many individuals treated with levodopa and it became obvious that more effective treatment was still sorely needed.

The knowledge that bromocriptine was a dopamine agonist led Donald Calne and his colleagues, initially at Hammersmith Hospital in London and later at the National Institutes of Health in Bethesda, to evaluate bromocriptine in patients with PD. Clinical trials with two earlier dopamine agonists, apomorphine (30) and piribedil (31), had been disappointing due to adverse effects, but Calne and colleagues found that bromocriptine at doses up to 30mg daily, when added to levodopa, was tolerated and provided improvement in motor function (32). Subsequent studies reported that bromocriptine in doses up to 100mg daily provided improvement both as monotherapy and when used in conjunction with levodopa and that at higher doses, a therapeutic effect comparable to levodopa could be achieved (28, 33 34, 35). The fact that bromocriptine, unlike levodopa which must be converted to dopamine by dopa decarboxylase, directly stimulates dopamine receptors was also considered to open the possibility that bromocriptine might be effective even in patients who were no longer responding adequately to levodopa. The success of bromocriptine soon led to the development of an expanding array of still newer dopamine agonists.

As the potential role for bromocriptine and other dopamine agonists in the treatment of PD was unfolding, another landmark advance in the understanding of dopaminergic function was emerging, culminating in the proposal in 1979 by John Keabian and Donald Calne that there are two distinct categories of dopamine receptor, which they designated D1 and D2 (36). Subsequent research utilizing molecular biological techniques expanded the number of dopamine receptors to five, but the five could still be placed within the two dopamine receptor families described earlier (37). This further fueled the search for additional dopamine agonists, with the hope that dopamine agonists selective for striatal dopamine receptors could be discovered that would be even more effective and less likely to produce adverse effects.

The 1980s and 1990s were an era of proliferation of dopamine agonists, with the introduction of lergotrile, lisuride, pergolide, mesulergine, cabergoline and others. Like bromocriptine, all were selective for the D2 receptor family, with some variability in subtype selectivity. It is unfortunate and perhaps surprising that no selective D1 receptor agonist ever passed the pharmacological gauntlet to human use. The promise of precisely selective dopamine receptor agonists was not achieved. During these years, controversy swirled around the question of whether PD treatment should begin with levodopa or with a dopamine agonist such as bromocriptine. Those favoring levodopa pointed to its superior efficacy and lower likelihood of producing psychiatric toxicity; those favoring dopamine agonists focused on the reduced risk of developing motor fluctuations with dopamine agonists and suggested that levodopa itself may be toxic to dopamine neurons by means of free radical production. The concept of using bromocriptine and other dopamine agonists as a levodopa-sparing treatment strategy was...
popularized and it was not until a number of years later that the idea of levodopa toxicity was disproven (38) and what was labeled by some as “levodopa phobia” (39) was placed to rest.

It is not correct to say, however, that there were no differences between the various dopamine agonists and it was one important difference that led to the demise of bromocriptine as the primary dopamine agonist used in the treatment of PD. Several of the dopamine agonists (bromocriptine, pergolide, cabergoline) were ergot derivatives, and with the increasing use of high-dose bromocriptine therapy in the treatment of PD in the 1980s, some adverse effects began to appear that could be traced to the ergot properties of the drugs. The appearance of pleuropulmonary changes in PD patients following prolonged administration of bromocriptine was first reported by Rinne in 1981 (40). Over the next several years, a growing number of reported cases surfaced and in 1988, McElvaney and colleagues suggested that the prevalence of pleuropulmonary changes in individuals with PD treated with bromocriptine was in the range of 2–5% (41). Constrictive pericarditis, valvular heart disease and retroperitoneal fibrosis also were reported predominantly at doses at or above 20mg/day when dosed multiple times during the day. The recognition that these complications of therapy, although often reversible following discontinuation of the offending drug, could be avoided by using one of the non-ergot dopamine agonists such as ropinirole or pramipexole, which had been approved for use in the USA in 1997, led to a gradual abandonment of bromocriptine as the primary dopamine agonist therapy for PD. The recognition of other treatment complications, such as excessive sleepiness and impulse control disorders, in more recent years has further tempered the enthusiasm for the use of dopamine agonists, although they still retain an important place in the treatment armamentarium, both for PD and for restless legs syndrome. Although bromocriptine has largely passed from the PD treatment stage, it has left a lasting legacy as the pioneer dopamine agonist first successfully employed in the treatment of PD.

Bromocriptine is approved in the USA for the treatment of hyperprolactinemia-associated dysfunctions including pituitary tumors, acromegaly and PD. It has been used for multiple other indications and after the first 10 years, Prof. Flückiger, Donald Calne and Thorner wrote a monograph which discussed the state of art at that time and where it was being researched (42). In 2009, bromocriptine was approved for the treatment of diabetes mellitus type 2 (T2DM) at dosages generally much less than used for the treatment of PD or hyperprolactinemia or acromegaly. This is for a new formulation (Cycloset) which is dosed only once daily in the morning within 2h of waking and designed to be more rapidly absorbed and have a shorter duration of action (Table 1). Its role is described by deFronzo (43). It appears to have great promise but has not been widely adopted as yet. At doses of 1.6–4.8mg/day, it lowers HbA1c in T2DM subjects by 0.5–0.9 as add-on therapy to oral anti-diabetes agents and by 1.1–1.8 as add-on therapy to metformin plus basal/bolus insulin (44). This Cycloset effect appears to be mainly (though not solely) via action on postprandial hyperglycemia. Circadian-timed Cycloset also reduces fasting and postmeal plasma free fatty acid and triglyceride levels. It was shown in a randomized, double-blind, 1-year safety study of some ~3000 patients to lower the composite cardiovascular endpoint of myocardial infarction, stroke, hospitalization for congestive heart failure, unstable angina and revascularization surgery by 39% (45). This may be due to its lowering of sympathetic drive due to an action at the ventromedial nucleus of the hypothalamus and through connections to the suprachiasmatic nucleus that affect sympathetic outflow to the periphery (44). Studies performed in experimental model of the SHR rat demonstrate that injection of bromocriptine once daily 1 hour before lights off leads to remarkable changes including: reduced ventromedial hypothalamic

| Table 1 | Comparison of key bioavailability characteristics of Cycloset and Parlodel. |
|--------------------------|---------------------------------|--------------------------|
| **Bromocriptine form**   | Micronized to specific particle size distribution to generate specific dissolution profile | Non-micronized |
| **Bioavailability (absorbed dose)** | 65–95% | 28% |
| **Unabsorbed dose** | 5–25% | 72% |
| **Time to maximum plasma level** | 53 min | 1–3 h |
| **Elimination half life** | 6 h | 15 h |
| **Approved indication** | Glycemic control | Parkinson’s disease and endocrine-related diseases |

Parlodel (package insert). Suffern, NY, and East Hanover, NJ; Novartis Pharmaceuticals Corporation, 2006; Cycloset Package Insert 2016; and VeroScience LLC, Tiverton, RI. Reproduced with Permission from Anthony Cincotta, VeroScience LLC.
norepinephrine and serotonin levels to the normal range and systolic and diastolic blood pressures, retroperitoneal body fat, plasma insulin and glucose levels and HOMA-IR relative to vehicle-treated SHR controls. Such treatment also reduced plasma levels of C-reactive protein, leptin and norepinephrine and increased those of plasma adiponectin significantly relative to SHR controls. Finally, bromocriptine treatment significantly reduced hepatic levels of several proinflammatory pathway proteins and of the master transcriptional activators of lipogenesis, gluconeogenesis and free fatty acid oxidation versus control SHR rats (46). Cincotta and colleagues, who have pioneered this work, draw the analogy of the change in fat mass, insulin resistance in seasonal vertebrates to prepare them for their needs when famine or short supply of food occurs. The hepatic metabolism appears to be regulated by the clock pacemaker. Seasonally obese, insulin-resistant animals evolved the ability to become hepatic insulin resistant to generate glucose when little to none is available in the wild and yet increase insulin-mediated hepatic lipogenesis to generate lipid as a fuel source for non-CNS tissue to thereby spare the produced hepatic glucose for the brain. Thus, it is suggested that metabolic syndrome and type 2 diabetes may be a maladaptation since humans fortunately in the modern world are less frequently exposed to food deprivation. Perhaps, timed bromocriptine may prevent them from developing metabolic syndrome and its associated morbidity. Fifty years later, there are still many questions that remain, but the journey continues to have interesting and potentially important therapeutic implications.

Declaration of interest
Dr Besser has no declarations of interest or funders and Dr Thorner is the founder and Chief Scientific Officer of Ammonett Pharma which is developing MK-0677 (butamoren) as ghrelin receptor agonist. None of the authors have any interests in the dopamine agonists at the time of developing MK-0677 (ibutamoren) as ghrelin receptor agonist. None of Dr Besser has no declarations of interest or funders and Dr Thorner is important therapeutic implications.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References

www.eje-online.org


36 Kebabian JW & Calne DB. Multiple receptors for dopamine. Nature 1979 277 93–96. (https://doi.org/10.1038/277093a0)


Received 1 May 2018
Accepted 11 May 2018